Author: claimsbot

1. A method comprising:
receiving a status inquiry from an agent regarding the status of a set of monitoring instructions, the monitoring instructions regarding monitoring the availability of applications, the inquiry including a time stamp for the set of instructions;
comparing the time stamp received from the agent to a time stamp for an up-to-date set of monitoring instructions for the agent; and
sending the up-to-date set of monitoring instructions to the agent if the time stamp of the up-to-date monitoring instructions is later than the time stamp received from the agent.
2. The method of claim 1, further comprising sending a message to the agent indicating that the set of monitoring instructions are up-to-date if the data stamp of the up-to-date set of monitoring instructions is not later than the time stamp received from the agent.
3. The method of claim 1, wherein the set of instructions instructs the agent to monitor the availability of one or more systems.
4. The method of claim 1, wherein the time stamp comprises the time that the set of monitoring instructions became effective.
5. The method of claim 1, further comprising receiving monitoring data from the agent.
6. The method of claim 1, further comprising providing a second set of monitoring instructions to a second agent.
7. The method of claim 6, wherein the set of the monitoring instructions and the second set of monitoring instructions overlap in whole or in part.
8. An system comprising:
a monitoring agent, the monitoring agent to receive a work list of systems to monitor for the availability of applications, the work list including an effective time value; and
a central monitoring system, the central monitoring system including a current work list for the monitoring agent, the current work list including a effective time value, the control system to send the current work list to the monitoring agent if the effective time value for the current work list is later than the effective time value of the monitoring agent’s work list.
9. The system of claim 8, further comprising a second agent, the second agent to receive a second work list of systems to monitoring for the availability of applications, the second work list including an effective time value.
10. The system of claim 9, wherein central monitoring system includes a second current work list for the second agent, the second current work list including an effective time value, the central monitoring system to send the second current work list to the second agent if the effective time value for the current list is later than the effective time value of the second agent’s work list.
11. The system of claim 9, wherein the work list of the first agent and the work list of the second agent provide at least in part for monitoring of the availability of applications on the same system.
12. The system of claim 8, wherein the one or more systems includes a first system, the first system being an J2EE (Java 2, Enterprise Edition) system.
13. The system of claim 11, wherein the one or more systems includes a second system, the second system being an ABAP (Advanced Business Application Programming) system.
14. The system of claim 8, wherein the agent is autonomous in execution of the work list.
15. The system of claim 8, wherein the agent obtains data from the monitoring of the availability of applications and transfers the data to the central monitoring system.
16. A machine-readable medium having stored thereon data representing sequences of instructions that, when executed by a processor, cause the processor to perform operations comprising:
receiving a status inquiry from an agent regarding the status of a set of monitoring instructions, the monitoring instructions regarding monitoring the availability of applications, the inquiry including a time stamp for the set of instructions;
comparing the time stamp received from the agent to a time stamp for an up-to-date set of monitoring instructions for the agent;
sending the up-to-date set of monitoring instructions to the agent if the time stamp of the up-to-date monitoring instructions is later than the time stamp received from the agent; and
sending message to the agent indicating that there is no change in instructions if the data stamp of the up-to-date set of monitoring instructions is not later than the time stamp received from the agent.
17. The medium of claim 16, wherein the set of instructions instructs the agent to monitor the availability of one or more systems.
18. The medium of claim 16, further comprising instructions that, when executed by the processor, cause the processor to perform operations comprising:
sending a second set of monitoring instructions to a second agent, the second set of monitoring instructions including a second time stamp.
19. The medium of claim 18, further comprising instructions that, when executed by the processor, cause the processor to perform operations comprising:
receiving a status inquiry from the second agent, the inquiry including the second time stamp; and
comparing the second time stamp to a time stamp for an up-to-date set of monitoring instructions for the second agent.
20. The medium of claim 19, further comprising instructions that, when executed by the processor, cause the processor to perform operations comprising:
sending the up-to-date set of monitoring instructions for the second agent to the second agent if the time stamp of the up-to-date monitoring instructions is later than the time stamp received from the second agent; and
sending a message to the second agent indicating that there is no change in instructions if the data stamp of the up-to-date set of monitoring instructions is not later than the time stamp received from the second agent.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of formulating a latent doping composition comprising:
providing at least one polymer comprising conjugation in the polymer backbone,
providing at least one dopant for the polymer,
providing at least one solvent,
formulating the polymer, the dopant, and the solvent to form the composition wherein the composition consists essentially of the polymer, the dopant, and the solvent, and wherein the dopant does not substantially dope the polymer when the composition is formulated, but does substantially react with the polymer when the solvent is removed; wherein the polymer comprises regioregular polythiophene, the dopant is an organic dopant, and the solvent is a polar solvent; wherein the amount of polymer is from about 0.01 wt. % to about 20 wt. %, wherein the amount of dopant is from about 0.01 wt. % to about 6 wt. %, and the amount of solvent is from about 80 wt. % to about 99.9 wt. %, and
further comprising the step of removing solvent to form a film of doped polymer.
2. The method according to claim 1, wherein the amount of polymer is from about 0.01 wt. % to about 6 wt. %, wherein the amount of dopant is from about 0.01 wt. % to about 6 wt. %, and the amount of solvent is from about 94 wt. % to about 99.9 wt. %.
3. The method according to claim 1, wherein the composition further consists essentially of at least one additional material.
4. The method according to claim 1, wherein the polymer has a number average molecular weight of 2,000 to 25,000.
5. The method according to claim 1, wherein the polymer has a number average molecular weight of 3,000 to 20,000.
6. The method of claim 1, wherein the dopant does not substantially dope the polymer for at least ten minutes after formulation and storage at 25\xb0 C.
7. The method of claim 1, wherein the dopant does not substantially dope the polymer for at least thirty days after formulation and storage at 50\xb0 C.

1. A balancing device for turbocompressors comprising a base structure which supports elastically a supporting structure which has a flange for supporting a receptacle of a rotating element, the balancing device further comprising the rotating element, said rotating element being movable with a rotary motion about its own rotation axis, the balancing device further comprising actuation means adapted to actuate lever means along a substantially radial direction, said lever means being adapted to generate a force for fixing said receptacle to said flange in a direction which is substantially parallel to said rotation axis.
2. The balancing device according to claim 1, wherein elastic elements are disposed between said actuation means and said lever means, the elastic elements being elastic in a substantially radial direction and are adapted to uncouple mechanically said actuation means from said lever means.
3. The balancing device according to claim 2, wherein in said lever means a power arm to which the force of said actuation means is applied, in said substantially radial direction, is longer than a resistance arm that generates the force for fixing in said direction which is substantially parallel to said rotation axis.
4. The balancing device according to claim 1, wherein said lever means are adapted to perform a translational movement in a radial direction and to rotate on a plane that passes through said rotation axis.
5. The balancing device according to claim 4, wherein said supporting structure comprises a portion which forms a substantially elliptical slot, said lever means comprising a pivot which engages said slot to allow said translation and said rotation of said lever means.
6. The balancing device according to claim 1, further comprising retention means which are interposed between said actuation means and said lever means and are adapted to delay rotation of said lever means.
7. The balancing device according to claim 6, wherein said retention means are comprised between a protrusion of said lever means which is directed radially toward said actuation means and the actuation means themselves.
8. The balancing device according to claim 1, wherein said actuation means are mounted in pairs arranged on the same diameter.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound having the formula:
or a physiologically acceptable salt thereof, wherein R1 is a halogen.
2. The compound of claim 1 wherein R1 is selected from the group consisting of chloro, fluoro and bromo.
3. The compound of claim 2 wherein R1 is chloro.
4. A pharmaceutical composition comprising the compound of claim 1 and a physiologically acceptable carrier or excipient.
5. A compound having the structure:
or a physiologically acceptable salt thereof, wherein R1 is a halogen.
6. The compound of claim 5 wherein R1 is selected from the group consisting of chloro, fluoro and bromo.
7. The compound of claim 6 wherein R1 is chloro.
8. A pharmaceutical composition comprising the compound of claim 5 and a physiologically acceptable carrier or excipient.
9. A method of treating a disease selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemiareperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
10. A compound having the formula:
or a physiologically acceptable salt thereof, wherein R1 is a halogen.
11. A pharmaceutical composition comprising the compound of claim 10 and a physiologically acceptable carrier or excipient.
12. The compound of claim 10 wherein R1 is selected from the group consisting of chloro, fluoro and bromo.
13. The compound of claim 12 wherein R1 is chloro.
14. A method of treating a disease selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemiareperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
15. A method of treating a disease selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemiareperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
16. A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
17. The method of claim 16, wherein said inflammatory disease is an acute inflammatory disease.
18. The method of claim 16, wherein said inflammatory disease is a chronic inflammatory disease.
19. A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
20. The method of claim 19, wherein said inflammatory disease is an acute inflammatory disease.
21. The method of claim 19, wherein said inflammatory disease is a chronic inflammatory disease.
22. A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
23. The method of claim 22 wherein said inflammatory disease is an acute inflammatory disease.
24. The method of claim 22 wherein said inflammatory disease is a chronic inflammatory disease.
25. A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
26. The method of claim 25 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter’s syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
27. A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
28. The method of claim 27 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter’s syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
29. A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
30. The method of claim 29 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter’s syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
31. A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
32. The method of claim 31 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
33. The method of claim 32 wherein said acute inflammatory demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
34. The method of claim 31 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
35. The method of claim 34 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
36. A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
37. The method of claim 36 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
38. The method of claim 37 wherein said acute inflammatory demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
39. The method of claim 36 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
40. The method of claim 39 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
41. A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
42. The method of claim 41 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
43. The method of claim 42 wherein said acute inflammatory demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
44. The method of claim 41 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
45. The method of claim 44 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
46. A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
47. A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
48. A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
49. A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
50. A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
51. A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.